Good news for our furry and scaly friends: Molecular diagnostics firm Lumora just entered into a license and development agreement with Biogal Galed Labs ACS, a provider of veterinary diagnostics, to develop a series of veterinary tests. The partnership will reportedly allow Biogal Galed Labs ACS to access Lumora’s enabling technologies such as BART (Bioluminescent Assay in Real Time), as well as the company’s experience with test development, reader technologies, and manufacturing.
The partnership will involve a pipeline of test development starting with leptospirosis, a zoonotic bacterial infection transmitted through the urine of animals. “With the leptospirosis test progressing through development, we have already initiated work on a series of additional assays in the planned development pipeline,” said Laurence Tisi, CEO of Lumora.
The deal with Biogal, according to Lumora, follows a series of milestones for the firm this year, including a partnership with FIND (Foundation for Innovative Novel Diagnostics) in April to develop a novel malaria diagnostic, a new fundraising round in March, and the appointment of new team members including a new commercial director (Hayden Jeffreys, formerly divisional director, diagnostic products at Lab21) and chairman (Jim Reid, who won the Ernst & Young Entrepreneur of the Year for Science and Technology in 2005).